These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 21806477)
1. Is there still room for large registrative trials in unselected cancer patients? The case of anti-epidermal growth factor receptor antibodies in advanced non-small-cell lung cancer. Di Maio M Expert Opin Biol Ther; 2011 Sep; 11(9):1131-3. PubMed ID: 21806477 [TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies against EGFR in non-small cell lung cancer. Pirker R; Filipits M Crit Rev Oncol Hematol; 2011 Oct; 80(1):1-9. PubMed ID: 21109448 [TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of monoclonal antibodies in non small cell lung cancer. Filipits M J BUON; 2009 Sep; 14 Suppl 1():S147-52. PubMed ID: 19785057 [TBL] [Abstract][Full Text] [Related]
4. Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development. Dienstmann R; Felip E Expert Opin Biol Ther; 2011 Sep; 11(9):1223-31. PubMed ID: 21679088 [TBL] [Abstract][Full Text] [Related]
5. Controversies around the use of monoclonal antibodies in the treatment of advanced non-small cell lung cancer. Dediu M; Ion O; Ion R; Gal C; Median D; Gongu M J BUON; 2009 Sep; 14 Suppl 1():S159-64. PubMed ID: 19785059 [TBL] [Abstract][Full Text] [Related]
6. Is there a role for cetuximab in non small cell lung cancer? Morgensztern D; Govindan R Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4602-5. PubMed ID: 17671149 [TBL] [Abstract][Full Text] [Related]
7. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. Agelaki S; Georgoulias V Expert Opin Emerg Drugs; 2005 Nov; 10(4):855-74. PubMed ID: 16262567 [TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update. Pirker R Curr Opin Oncol; 2015 Mar; 27(2):87-93. PubMed ID: 25636162 [TBL] [Abstract][Full Text] [Related]
9. Cetuximab in non-small-cell lung cancer. Carillio G; Montanino A; Costanzo R; Sandomenico C; Piccirillo MC; Di Maio M; Daniele G; Giordano P; Bryce J; Normanno N; Rocco G; Perrone F; Morabito A Expert Rev Anticancer Ther; 2012 Feb; 12(2):163-75. PubMed ID: 22316364 [TBL] [Abstract][Full Text] [Related]
11. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Maione P; Gridelli C; Troiani T; Ciardiello F Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812 [TBL] [Abstract][Full Text] [Related]
12. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. García B; Neninger E; de la Torre A; Leonard I; Martínez R; Viada C; González G; Mazorra Z; Lage A; Crombet T Clin Cancer Res; 2008 Feb; 14(3):840-6. PubMed ID: 18245547 [TBL] [Abstract][Full Text] [Related]
13. The current status of targeted therapy for non-small cell lung cancer. Francis H; Solomon B Intern Med J; 2010 Sep; 40(9):611-8. PubMed ID: 20002849 [TBL] [Abstract][Full Text] [Related]
14. The evolving role of cetuximab in non-small cell lung cancer. Lilenbaum RC Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4432s-4435s. PubMed ID: 16857823 [TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Heymach JV; Nilsson M; Blumenschein G; Papadimitrakopoulou V; Herbst R Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4441s-4445s. PubMed ID: 16857825 [TBL] [Abstract][Full Text] [Related]
16. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor. Crawford J J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580 [TBL] [Abstract][Full Text] [Related]